# **Key Investor Information**

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

## Health Care Innovators, a Subfund of the SICAV BNP Paribas Funds, short named as BNP Paribas

Class "Classic Distribution" - ISIN code LU0823416929

This Fund is managed by BNP PARIBAS ASSET MANAGEMENT Luxembourg, part of the BNP Paribas Group

#### **Objectives and Investment Policy**

The Fund seeks to increase the value of its assets over the medium term by investing in shares issued worldwide by companies which innovate or benefit from healthcare innovation including but not limited to advances in genetic sequencing, drug delivery, miniaturization, bio-compatible materials, haptics and information technology in the healthcare field.

It is actively managed and as such may invest in securities that are not included in the index which is MSCI World Health Care 10/40 (NR).

The investment team applies also BNP PARIBAS ASSET MANAGEMENT Sustainable Investment Policy, which takes into account Environmental, Social and Governance (ESG) criteria in the investments of the Fund.

A dividend may be distributed.

Investors are able to redeem on a daily basis (on Luxembourg bank business days).

#### Risk and Reward Profile

Lower risk						Higher risk		<
	Typically lov	ver reward				Typically h	igher reward	1
	1	2	3	4	5	6	7	

- Historical data may not be reliable indication for the future.
- The risk category of a Fund is an indicator but not a target or a guarantee and may shift over time.
- The lowest category does not mean a risk-free investment.
- Why is the Fund in this specific category?

The risk category is justified by the investment mainly in Stocks and Shares, the value of which can fluctuate considerably. These fluctuations are often amplified in the short term.

• The higher the risk, the longer the recommended investment horizon.

Other risks materially relevant to the Fund which are not adequately captured by the indicator are described below:

- Liquidity Risk: This risk arises from the difficulty of selling an asset at a fair market price and at a desired time due to lack of buyers.
- Operational and Custody Risk: Some markets are less regulated than most of the international markets; hence, the services related to custody and liquidation for the subfund on such markets could be more risky.


For more information on risks, please see the "Investment risks" section of the Fund's prospectus, which is available at **www.bnpparibas-am.com**.

#### Charges

The charges you pay are used to pay the Fund's running costs, including the costs of marketing and distribution. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest			
Entry charge	3.00%		
Exit charge	xit charge     No       his is the maximum that might be taken out of your money (before the roceeds of your investment are paid out).       harges taken from the Fund over each year		
0			
Charges taken from the Fund over			
Ongoing charges	1.95%		
Charges taken from the fund under	ges taken from the fund under specific conditions		
Performance fee	No		

#### Past Performance



Health Care Innovators ClassicBenchmark

A: 04/1997-05/2013: Following a corporate action on 17/05/2013, the performances listed are the simulated past performance and fees of the BNP PARIBAS L1 EQUITY WORLD HEALTH CARE.

B: 2014-2017: During this period, a different investment policy was implemented.

### Practical information

- Custodian: BNP PARIBAS SECURITIES SERVICES-LUXEMBOURG BRANCH
- Further information about the Fund including the latest Prospectus, latest published prices of share(s), annual report and half yearly report may be obtained free
  of charge, in English, from BNP PARIBAS ASSET MANAGEMENT Luxembourg or online at <u>www.bnpparibas-am.com.</u>
- Luxembourg tax legislation may have an impact on the personal tax position of the investor.
- Details of the updated remuneration policy (including a description of how the remuneration and benefits are calculated), the identity of the people responsible for
  granting the remuneration and benefits and the composition of the remuneration committee are available on the website
  <u>http://www.bnpparibas-</u>
  <u>am.com/en/remuneration-disclosure/</u>. A hard copy of the remuneration policy will be available upon request.
- BNP PARIBAS ASSET MANAGEMENT Luxembourg may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.
- Investors may switch between Funds of BNP Paribas Funds. Please see the prospectus or contact your financial adviser for details.
- Information for investors in Switzerland: the Prospectus, the Key Investor Information Document, the Articles of Association as well as the annual and semiannual reports can be obtained, free of charge, from the representative in Switzerland, BNP Paribas Securities Services, Paris, succursale de Zurich, 16, Selnaustrasse, 8002 Zurich ; the paying agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, 16, Selnaustrasse, 8002 Zurich

This Fund is authorised in Grand Duchy of Luxembourg and regulated by the "Commission de Surveillance du Secteur Financier". This key investor information is accurate as at 19 February 2020.



ASSET MANAGEMENT

The **entry charges** shown are maximum figures. In some cases you might pay less. You can find this out from your financial adviser.

The **ongoing charges** figure shown here is an estimate of the charges. Due to recent change in the fees structure, an estimate is used rather than an ex-post figure. This figure may vary from year to year. It excludes:

 Portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units in another collective investment undertaking.
 In case of conversion, the investors may be charged a maximum fee of 1.50%.

For more information about charges, please see the "Fees and Costs" section of the Fund's prospectus, which is available at <u>www.bnpparibas-am.com</u>.

- Performance figures are shown for shares classes, for which NAV was continuously calculated during the period from 1st January to 31st December.
- Past performance is not an indicator of future results.
- The ongoing charges of the Fund are included in the calculation of past performance. The entry/exit and conversion fees are excluded from the calculation of the past performance.
- The share class came into existence in 2013
- Past performance has been calculated in EUR
- Performance returns are based on the net asset value with distribuable income reinvested.